LIDDS is a company built on research and development. The company has developed a unique drug delivery technology, which has been utilized in the generation of an oncology pipeline of in-house and partnered programs from early to late stage development. The pipeline represents LIDDS ambition to develop better and safer treatments for patients that have a strong value to global pharma companies. This is done by maximizing the efficacy by efficient targeting of diseased part of the body while minimizing off-target accumulation to avoid systemic side effects.
Pipeline
Pipeline
Nanodotax
Nanodotax is NanoZolid-formulated docetaxel which is a commonly used chemotherapeutic drug that has been approved for several oncological conditions. Nanodotax has shown to be safe and well tolerated in a phase I study. In addition there was an observed effect on systemic and local immunological biomarkers indicating that the immune system was responding positively and specifically to the treatment.
Nanoimod
Nanoimod is the toll-like receptor 9 (TLR9) agonist agatolimod formulated in NanoZolid®. The project is in preclinical development and is being prepared for a Phase Ib clinical study in multiple cancer indications in addition to treatment with Checkpoint inhibitors.
NOV 202
The combination of the compound NOV202 and PARP inhibitors have shown very promising synergistic antitumoral effects in several tumour models. The combination of NOV202 and several PARP inhibitors on the market have shown improved efficacy compared to any of the pharmaceuticals given alone. Examples of preclinical cancer models used are models for ovarian-, pancreatic- and prostate cancer.